| Basics |
Omeros Corporation
Omeros Corp is a biopharmaceutical company. It focuses on research and development of small-molecule and protein therapeutics to treat inflammation, coagulopathies, and disorders of the central nervous system and sells Omidria for cataract surgeries.
|
| IPO Date: |
October 8, 2009 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$769.27M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.31 | 3.19%
|
| Avg Daily Range (30 D): |
$0.36 | 4.51%
|
| Avg Daily Range (90 D): |
$0.23 | 3.57%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.57M |
| Avg Daily Volume (30 D): |
1.46M |
| Avg Daily Volume (90 D): |
2.43M |
| Trade Size |
| Avg Trade Size (Sh.): |
137 |
| Avg Trade Size (Sh.) (30 D): |
100 |
| Avg Trade Size (Sh.) (90 D): |
108 |
| Institutional Trades |
| Total Inst.Trades: |
1,241 |
| Avg Inst. Trade: |
$1.45M |
| Avg Inst. Trade (30 D): |
$1.27M |
| Avg Inst. Trade (90 D): |
$1.29M |
| Avg Inst. Trade Volume: |
.11M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.52M |
| Avg Closing Trade (30 D): |
$.96M |
| Avg Closing Trade (90 D): |
$1.13M |
| Avg Closing Volume: |
123.28K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-2.02
|
$-.47
|
$-.43
|
|
Diluted EPS
|
|
$-.47
|
$-.43
|
|
Revenue
|
$ M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -121.16M
|
$ -30.92M
|
$ -25.42M
|
|
Operating Income / Loss
|
$ -129.38M
|
$ -26.39M
|
$ -32.35M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ .87M
|
$ .49M
|
$ -2.36M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Oct 02, 2009:
25:49
|
|
|
|
